GSK Enters Partnership With Flagship Pioneering to Develop Up to 10 New Drugs
By Helena Smolak
GSK entered into a partnership with U.S. biotech Flagship Pioneering to identify new medicines and vaccines, in a move to further boost its pipeline.
The British pharma giant said Monday that its deal with the bioplatform innovation company aims to start with identifying a portfolio of 10 drugs in the respiratory and immunology area, each subject to an exclusive option by GSK.
GSK and Flagship Pioneering will jointly fund up to $150 million of research. Flagship Pioneering and its bioplatform companies are eligible to receive up to $720 million upfront, including development and commercial milestones, preclinical funding and tiered royalties, for each program acquired by GSK, it said.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
July 29, 2024 07:36 ET (11:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now
United States